Faried Banimahd, MD
Addiction Medicine · Santa Ana, CANPI 1184860496
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,500 of the $7,229 with a category attached, or 89.9%. Masimo Corporation accounts for 90.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $6,500 and has fallen 98.9% since, to $69 in 2025. Among addiction medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $258.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Masimo Corporation$7K
- Gilead$301
- Indivior Inc.$296
- Braeburn Inc.$68
- Inari Medical, Inc.$29
- AbbVie$18
Across 3 payments — averaging $3027.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Masimo Corporation$9K
What the payments were for
- Consulting fees$6,50090%
- Food & beverage$72910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Masimo Corporation | 2 | $6,516 |
| Gilead | 8 | $301 |
| Indivior Inc. | 13 | $296 |
| Braeburn Inc. | 3 | $68 |
| Inari Medical, Inc. | 1 | $29 |
| AbbVie | 1 | $18 |
How this compares
$7,229 in reported general payments places this provider in the 90th percentile of 190 addiction medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 38 | $4,196 |
| Buprenorphine Hcl | 27 | $1,132 |
| Quetiapine Fumarate | 16 | $377 |
| Clonazepam | 24 | $188 |
| Diazepam | 23 | $155 |
| Gabapentin | 19 | $104 |
| Zolpidem Tartrate | 11 | $98 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Santa Ana
- Jonathan WatsonSanta Ana$3K
- Sunil GulayaSanta Ana$995
- Tipu KhanVentura$262K
- Anthony AlbaneseMather$135K
- Matthew TorringtonCulver City$77K
- Kenneth StarrArroyo Grande$64K
- Drew PinskySouth Pasadena$60K
- Mark HonzelBeverly Hills$27K
- Bryan HylerVista$17K
- Abraham MalkinLos Angeles$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.